期刊
GENES & DISEASES
卷 7, 期 3, 页码 328-335出版社
KEAI PUBLISHING LTD
DOI: 10.1016/j.gendis.2020.03.010
关键词
Anti-angiogenic therapy; Combinational therapy; Hepatocettutar carcinoma; Molecular targeted therapy; Systemic therapy
资金
- Leading Investigator Program of Shanghai municipal government [17XD1401100]
- National Key Basic Research Program (973 Program) [2015CB554005]
- National Natural Science Foundation of China [81372655, 81472224, 81672326]
Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angiogenic effects targeting the vascular endothelial growth factor signaling pathway. Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. Although anti-PD-1 antibodies, including nivolumab and pembrolizumab, demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials, both failed in phase III studies. Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies. Copyright (C) 2020, Chongqing Medical University. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据